Physician profile
Mais Hamdan
NPI 1669116026
$1,689.63
in general payments reported to CMS, 2019-2025
10 companies · $588 in 2025
The $588 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $89.51 · 2024: $774 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $368.94 | 2024 | |
| Novo Nordisk INC | $368.07 | 2022-2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.86 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $232.55 | 2023-2025 | Fasenra |
| Actelion Pharmaceuticals US, INC. | $129.83 | 2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $124.74 | 2025 | |
| Amgen INC. | $119.70 | 2022 | |
| Averitas Pharma INC. | $47.31 | 2025 | Qutenza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.25 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.38 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mais Hamdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.